Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1988 1
1989 4
1990 2
1991 3
1992 5
1993 3
1994 6
1995 5
1996 1
1997 1
1999 3
2000 7
2001 2
2002 3
2003 3
2004 12
2005 13
2006 18
2007 26
2008 24
2009 20
2010 30
2011 48
2012 38
2013 52
2014 66
2015 61
2016 70
2017 96
2018 108
2019 112
2020 126
2021 140
2022 135
2023 128
2024 149
2025 181
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,507 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Ying X, Jesudian AB. Ying X, et al. Gastroenterology. 2024 Feb;166(2):361. doi: 10.1053/j.gastro.2023.11.288. Epub 2023 Nov 24. Gastroenterology. 2024. PMID: 38008227 No abstract available.
An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis.
Vugler A, O'Connell J, Nguyen MA, Weitz D, Leeuw T, Hickford E, Verbitsky A, Ying X, Rehberg M, Carrington B, Merriman M, Moss A, Nicholas JM, Stanley P, Wright S, Bourne T, Foricher Y, Zhu Z, Brookings D, Horsley H, Heer J, Schio L, Herrmann M, Rao S, Kohlmann M, Florian P. Vugler A, et al. Among authors: ying x. Front Pharmacol. 2022 Nov 16;13:1037983. doi: 10.3389/fphar.2022.1037983. eCollection 2022. Front Pharmacol. 2022. PMID: 36467083 Free PMC article.
Reply.
Yao L, Ying X, Jesudian AB. Yao L, et al. Among authors: ying x. Gastroenterology. 2025 Nov;169(6):1316-1317. doi: 10.1053/j.gastro.2025.07.017. Epub 2025 Jul 21. Gastroenterology. 2025. PMID: 40701398 No abstract available.
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, Wang Y, Ba Y, Li N, Zhang R, Zhang J, Chen Y, Chen J, Huang M, Fu Y, Liu M, Liu Z, Zhao J, Li W, Wei J, Li C, Xu N, Guo Z, Cao B, Liu L, Nie P, Wan L, Sheng L, Liu Z, He Y, Gu K, Wu G, Wang W, Zhang F, Qiu W, Guo J, Ying J, Pan H, Xu H, Yuan Y, Bai Y, Wang Z, Xu J, Zhao X, Liu H, Zhang X, Dai W, Xu H, Liu M, Xie L, Tang Y, Jin J, Qu X, Fang X, Huang M, Chen H, Zheng Z, Wang Y, Wang D, Li X, Yu G, Liu H, Zhou Y, Zhong D, Zeng S, Kang M, Wang M, Gao Y, Li W, Wang Z, Zhang M, Zhang J, Li Q, Sun S, Zang A, Lin L, Xie M, Zhuang Z, Zhang T, Yao Z, Lu D, Liu W, Hu M, Wang ZM, Li B, Xia M, Zhang J, Ying X, Pardoll DM, Ji J. Shen L, et al. Among authors: ying x. Nat Med. 2025 Apr;31(4):1163-1170. doi: 10.1038/s41591-024-03450-4. Epub 2025 Jan 22. Nat Med. 2025. PMID: 39843940 Clinical Trial.
1,507 results